Fulcrum Therapeutics, Inc. (FULC) is an American biopharmaceutical company focused on creating and deploying products to treat genetically defined diseases that are underserved by conventional therapeutic approaches. This pioneering company works towards the development and commercialization of small molecule therapies designed to modulate gene expression.
Established in 2016, Fulcrum Therapeutics is based in Cambridge, Massachusetts. The company is a leader in the genetic medicine industry, evolving ways to understand and overcome the challenge of treating multifactorial genetic diseases. FULC uses an exclusive technology platform called “product engine”, which specifically targets genetic modulation, aiming to change the underlying disease pathogenesis.
Fulcrum Therapeutics’ lead product candidate, losmapimod, is designed to treat Facioscapulohumeral muscular dystrophy (FSHD), a severe and highly disabling disorder with no approved treatments. FSHD is a type of muscular dystrophy that primarily affects the skeletal muscles and causes progressive muscle weakness and loss of function. Losmapimod is a selective p38α/β mitogen-activated protein kinase (MAPK) inhibitor. It has demonstrated significant potential in early clinical trials in reducing DUX4 expression, a gene shown to be the root cause of FSHD.
The company is also developing a therapy for sickle cell disease and beta-thalassemia, two common genetic disorders affecting the hemoglobin in the red blood cells. The targeted therapy, called FTX-6058, is designed to upregulate fetal hemoglobin expression to address the root cause of these disorders.
The company's integrity, relentless drive, innovative spirit, and the drive to positively improve the lives of patients underscore its corporate culture. Fulcrum Therapeutics is led by an experienced group of researchers, scientists, and industry veterans deeply committed to bringing novel therapies to patients living with genetically defined diseases.
Through relentless scientific and clinical pursuit, Fulcrum Therapeutics aims to unlock new treatments for patients whose diseases currently have no effective therapeutic approaches. By harnessing the power of technology and innovation, the company seeks to pioneer major breakthroughs in the field of genetic medicine, committed to transforming lives and making a significant difference in the healthcare industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Fulcrum Therapeutics (FULC) has experienced a significant 51% stock decline over the past four weeks, placing it in oversold territory. Despite this, a potential trend reversal is indicated by its Relative Strength Index (RSI) of 21.62 and a 30% increase in consensus EPS estimates from Wall Street analysts over the last 30 days. The stock currently holds a Zacks Rank #2 (Buy), suggesting a strong possibility for a near-term turnaround.
Fulcrum Therapeutics (FULC) is undergoing an all-stock merger with Slate Medicines, transforming into a migraine-focused biotechnology company. The deal involves Slate holders owning 55.9%, PIPE investors 39.1%, and legacy Fulcrum holders 5% of the combined entity, with Fulcrum distributing an estimated $270 million cash dividend ($3.54/share). This transaction effectively offers Fulcrum shareholders a cash payout plus a small stake in Slate's migraine pipeline, which currently lacks human efficacy data.